Cabergoline (CAB) is a DA that has long been used off-label for the treatment of acromegaly due to its proven efficacy in normalizing IGF-I levels in one-third of cases in monotherapy and in up to 40–50% when used in combination with SSAs or PEG [3–5]. The gene discussed is IGF1; the disease is acromegaly.